secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2026-11-10T22:06:04+00:00
Accession:  0001087294-26-000076
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Cumberland posts Q3 net income of $77.8M on Apotex divestiture gain; plans ifetroban NDA in DMD
--------------------------------------------------------------------------------

- Net income of $77.8M in Q3 2026, driven by the gain on divestiture of commercial brands to Apotex Health, whose $100M strategic transaction closed July 1, 2026.
- Cash and equivalents of $80.6M at September 30, 2026; total assets ~$114M, liabilities $42M and shareholders' equity $73M.
- Will submit an NDA for ifetroban in DMD cardiomyopathy after a fall pre-NDA meeting; FDA granted a rolling review and conditionally accepted DYSCORBAN as the name.
- Phase 2 FIGHT DMD showed a 5.4 percentage point LVEF improvement (p=0.002) in the high-dose group; safety database exceeds 1,400 subjects across ~30 studies.
- Phase 2a ASSIST-SSc top-line: ifetroban generally well tolerated, no drug-related serious AEs over 12 months; Cumberland to submit the study report to FDA, SSc decision pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000108729426000076/0001087294-26-000076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000108729426000076/cpix-20261110.htm
  HTML page:      https://secwatch.observer/filing/0001087294-26-000076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer